BioSpace News Archive

Soliton, Inc.,, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, announced that the company has received approval for the trial protocol from the independent Institutional Review Board for its upcoming pivotal Cellulite Trial.

Emmaus Life Sciences, Inc. detailed the improved balance sheet, reduced debt service and other benefits realized from its recently completed merger transaction announced on July 17, 2019.

At the end of July 2019, the R&D pipeline contained 83 projects, including 34 new molecular entities in clinical development. 35 projects are in phase 3 or have been submitted to the regulatory authorities for approval.

With more than 40 years in the pharmaceutical industry, Peroxfarma announced earlier this year that it would roll-out a wide array of nutritional supplements

IONTAS Limited announced an agreement with Teva Pharmaceuticals to apply its technologies and know-how to the optimisation of human antibodies for use as biotherapeutics.

Existing investors also participated in the round to further Magenta’s development of miniaturized pumps to treat heart failure patients

The first quarter results press release will be issued on August 14, 2019 before the conference call.

Axonics Modulation Technologies, Inc. a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, announced the results from its ARTISAN-SNM study were published online in the peer-reviewed Journal of Urology.

Mylan N.V. announced its financial results for the three and six months ended June 30, 2019.

Company to hold second quarter 2019 conference call on August 8